Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?

A substantial body of evidence has accumulated to suggest a role for the xanthine oxidase metabolic pathway in the pathophysiology of chronic heart failure and other cardiovascular diseases

[1]  A. Struthers,et al.  Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure , 2005, Heart.

[2]  Joanne Brown,et al.  Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure , 2004, Expert opinion on investigational drugs.

[3]  H. Drexler,et al.  Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction: A New Action for an Old Drug? , 2004, Circulation.

[4]  G. Rosano,et al.  Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. , 2004, The American journal of cardiology.

[5]  R. Hambrecht.  Sport als Therapie , 2004, Herz.

[6]  A. Bolger,et al.  Beta-blockers for chronic heart failure: surviving longer but feeling better? , 2003, International journal of cardiology.

[7]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[8]  H. Ishizaka,et al.  Effect of Allopurinol Pretreatment on Free Radical Generation after Primary Coronary Angioplasty for Acute Myocardial Infarction , 2003, Journal of cardiovascular pharmacology.

[9]  P. Ponikowski,et al.  Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.

[10]  D. Harrison,et al.  Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure: Role of Xanthine-Oxidase and Extracellular Superoxide Dismutase , 2002, Circulation.

[11]  A. Struthers,et al.  Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.

[12]  Salim Yusuf,et al.  Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). , 2002, American heart journal.

[13]  Rainer Hambrecht,et al.  Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies , 2002, Circulation.

[14]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[15]  S. Anker,et al.  Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. , 2001, American heart journal.

[16]  W. Little,et al.  Allopurinol Enhances the Contractile Response to Dobutamine and Exercise in Dogs With Pacing-Induced Heart Failure , 2001, Circulation.

[17]  D. Mancini,et al.  Peak VO(2): a simple yet enduring standard. , 2000, Circulation.

[18]  S. Anker,et al.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. , 2000, Drugs.

[19]  D. Kass,et al.  Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. , 1999, Circulation research.

[20]  G. Bellomo,et al.  When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. , 1999, The Biochemical journal.

[21]  G. Schuler,et al.  Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.

[22]  E. Marbán,et al.  Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. , 1998, Circulation research.

[23]  S. Anker,et al.  Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. , 1997, European heart journal.

[24]  M. Netea,et al.  The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. , 1997, Blood.

[25]  H. Drexler,et al.  Physical training improves endothelial function in patients with chronic heart failure. , 1996, Circulation.

[26]  K. Raivio,et al.  Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[27]  J. Damen,et al.  Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. , 1995, Free radical biology & medicine.

[28]  T. Slater,et al.  Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. , 1994, The Journal of thoracic and cardiovascular surgery.

[29]  G. Rao,et al.  Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. , 1991, The Journal of biological chemistry.

[30]  Bakhtiiarov Za.  Changes in xanthine oxidase activity in patients with circulatory failure , 1989 .

[31]  Z. A. Bakhtiiarov.  [Changes in xanthine oxidase activity in patients with circulatory failure]. , 1989, Terapevticheskii arkhiv.

[32]  T. W. Keenan,et al.  Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium , 1981, Cell.

[33]  B. Lotti,et al.  Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism. , 1980, Biochemical pharmacology.